Your Article Summary
See Latest ArticlesA Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours
European Journal of Cancer, 06/26/09
Baruchel S et al. - In a study to evaluate the safety, efficacy, and pharmacokinetics of imatinib in children with recurrent or refractory central nervous system (CNS) tumours expressing KIT and/or PDGFRA, it was concluded that imatinib at 440 mg/m2/day is relatively safe in children with recurrent CNS tumours, but induced no objective responses. Demonstration of stable disease (SD) in previously progressing pts (KIT-expressing) suggests cytostatic activity of imatinib.
Methods- 19 pts aged 2–18 yrs, with recurrent or refractory CNS tumours expressing either of the target receptors KIT and/or PDGFRA (by immunohistochemistry) were eligible.
- Participants received imatinib orally at a dose of 440 mg/m2/day and toxicities and tumour responses were monitored.
- Serial blood and cerebrospinal fluid samples for pharmacokinetics were obtained in a subset of consenting pts.
- Frozen tumour samples were analysed retrospectively for KIT and PDGFRA gene amplification in a subset of pts for whom samples were available.
- Common toxicities were lymphopaenia, neutropaenia, leucopaenia, elevated serum transaminases, and vomiting.
- No intratumoural haemorrhages were observed.
- Although there were no objective responses to imatinib, 4 pts had long-term stable disease (SD) (38–104 wks).
- Results suggest a possible relationship between KIT expression and maintenance of SD with imatinib treatment; KIT immunopositivity was seen in only 58% (11/19) of study participants overall, but in 100% of pts with SD at 38 wks.
- All pt tumours showed PDGFRA expression.
- Pharmacokinetic data showed a high interpatient variability, but corresponded with previously reported values.
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
Cancer Management and Research, 11/05/09
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide
Journal of Clinical Oncology, 11/12/09
Clinical Analysis of Novalis Stereotactic Radiosurgery for Brain Metastases
Journal of Korean Neurosurgical Society, 11/02/09
Today in Pediatric Heme/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09
Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study
Journal of Clinical Oncology, 11/19/09